An open label, comparative, multicentric study to assess the efficacy and safety of fixed dose combination tablets of Nebivolol & Indapamide (as sustained release) in comparison with Nebivolol tablets in patients suffering from hypertension

Cadila Healthcare Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex ï?³18 years of age
•(No upper age limit was mentioned in our Protocol for this clinical trial).
•2.Patients with hypertension (defined as supine systolic and/or diastolic blood pressure more than 140 mm Hg and 90 mm Hg respectively)
•3.Informed consent of the patient/relative

•1.Pregnancy and/or Lactation
•2.Patients with anuria, progressive & severe oliguria, hepatic coma, hyponatremia, hypokalaemia, hyperuricemia, secondary hypertension, systemic lupus erythematosus
•3.Patients with bronchial asthma, diabetes, thyrotoxicosis, peripheral vascular disease, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure or sick sinus syndrome
•4.Patients with hepatic and /or renal dysfunction
•5.Patients with a history of known hypersensitivity to either Nebivolol or Indapamide or to other sulfonamide derivatives or to any other component of the study drugs
•6.Patients with any other serious concurrent illness or malignancy
•7.Patients with continuing history of alcohol and / or drug abuse
•8.Participation in another clinical trial in the past 3 months

发起方